Release according to article 40 para. 1 WpHG
Biofrontera AG: Release according to Article 40, Section 1 of the WpHG
Leverkusen, Germany (pta031/28.07.2022/17:35 UTC+2) - Release of Voting Rights Announcement
Voting Rights Announcement
1. Details of issuer
Name: | Biofrontera AG |
Legal Entity Identifier (LEI): | 391200D6GFSVFGFQTL13 |
Street: | Hemmelrather Weg 201 |
Postal code: | 51377 |
City: | Leverkusen, Germany |
2. Reason for notification
Acquisition / disposal of shares with voting rights
3. Details of person subject to the notification obligation
Natural person
(first name, surname):
Wilhelm K. T. Zours
Date of birth:
28.07.1961
4. Names of shareholders holding directly 3% or more voting rights, if different from 3.
DELPHI Unternehmensberatung Aktiengesellschaft
Deutsche Balaton Aktiengesellschaft
SPARTA AG
Deutsche Balaton Biotech AG
5. Date on which threshold was crossed or reached
26.07.2022
6. Total positions
% of voting rights attached to shares (total of 7.a.) | % of voting rights through instruments (total of 7.b.1 + 7.b.2) | Total of both in % (7.a. + 7.b.) | Total number of voting rights pursuant to Sec. 41 WpHG | |
---|---|---|---|---|
New | 30.01 | 2.91 | 32.92 | 56,717,385 |
Previous notification (if applicable) | 29.96 | 2.91 | 32.87 |
7. Details on total positions
a. Voting rights attached to shares (Sec.s 33, 34 WpHG)
ISIN | Absolute direct (Sec. 33 WpHG) | Absolute indirect (Sec. 34 WpHG) | In % direct (Sec. 33 WpHG) | In % indirect (Sec. 34 WpHG) |
---|---|---|---|---|
DE0006046113 | 0 | 17,021,057 | 0.00 | 30.01 |
Total: | 17,021,057 | 30.01 |
b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
type of instrument | Maturity / Expiration | Exercise or conversion period | Voting Rights Absolute | Voting Rights in % |
---|---|---|---|---|
0 | 0.00 | |||
Total: | 0 | 0.00 |
b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
type of instrument | Maturity / Expiration | Exercise or conversion period | Cash or physical transaction | Voting Rights Absolute | Voting Rights in % |
---|---|---|---|---|---|
Exchangeable Bond | 28.12.2022 | 31.03.2021 to 16.12.2022 | n/a | 1,650,000 | 2.91 |
Total: | 1,650,000 | 2.91 |
8. Information in relation to the person subject to the notification obligation
Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity
Name | % of voting rights (if at least 3% or more) | % of voting rights through instruments (if at least 5% or more) | Total of both (if at least 5% or more) |
---|---|---|---|
- Wilhelm K. T. Zours | |||
- DELPHI Unternehmensberatung Aktiengesellschaft | 30.01 | 30.01 | |
- VV Beteiligungen Aktiengesellschaft | |||
- Deutsche Balaton Aktiengesellschaft | 30.01 | 32.92 | |
- Heidelberger Beteiligungsholding AG | 30.01 | 30.01 | |
- | |||
- Wilhelm K. T. Zours | |||
- DELPHI Unternehmensberatung Aktiengesellschaft | 30.01 | 30.01 | |
- VV Beteiligungen Aktiengesellschaft | |||
- Deutsche Balaton Aktiengesellschaft | 30.01 | 32.92 | |
- SPARTA AG | 30.01 | 30.01 | |
- | |||
- Wilhelm K. T. Zours | |||
- DELPHI Unternehmensberatung Aktiengesellschaft | 30.01 | 30.01 | |
- VV Beteiligungen Aktiengesellschaft | |||
- Deutsche Balaton Aktiengesellschaft | 30.01 | 32.92 | |
- Deutsche Balaton Biotech AG | 30.01 | 30.01 |
9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)
Date of general meeting: N/A
Holding total positions (6.) after general meeting:
Proportion of voting rights | Proportion of instruments | Total of both |
---|---|---|
% | % | % |
10. Other useful information
Date
28.07.2022
(end)
Emitter: |
Biofrontera AG Hemmelrather Weg 201 51377 Leverkusen Germany |
|
---|---|---|
Contact Person: | Investor Relations | |
Phone: | +49 (0) 214 87 63 20 | |
E-Mail: | ir@biofrontera.com | |
Website: | www.biofrontera.com | |
ISIN(s): | DE0006046113 (Share) | |
Stock Exchange(s): | Regulated Market in Dusseldorf, Frankfurt; Free Market in Berlin, Munich, Stuttgart, Tradegate | |
Other Stock Exchanges: | US OTC |